We identified the previously unknown structures of ribosylated imidazoleacetic acids in rat, bovine, and human tissues to be imidazole-4-acetic acid-ribotide (IAA-RP) and its metabolite, imidazole-4-acetic acid-riboside. We also found that IAA-RP has physicochemical properties similar to those of an unidentified substance(s) extracted from mammalian tissues that interacts with imidazol(in)e receptors (I-Rs). [''Imidazoline,'' by consensus (International Union of Pharmacology), includes imidazole, imidazoline, and related compounds. We demonstrate that the imidazole IAA-RP acts at I-Rs, and because few (if any) imidazolines exist in vivo, we have adopted the term ''imidazol(in)e-Rs.''] The latter regulate multiple functions in the CNS and periphery. We now show that IAA-RP (i) is present in brain and tissue extracts that exhibit I-R activity; (ii) is present in neurons of brainstem areas, including the rostroventrolateral medulla, a region where drugs active at I-Rs are known to modulate blood pressure; (iii) is present within synaptosome-enriched fractions of brain where its release is Ca 2؉ -dependent, consistent with transmitter function; (iv) produces I-R-linked effects in vitro (e.g., arachidonic acid and insulin release) that are blocked by relevant antagonists; and (v) produces hypertension when microinjected into the rostroventrolateral medulla. Our data also suggest that IAA-RP may interact with a novel imidazol(in)e-like receptor at this site. We propose that IAA-RP is a neuroregulator acting via I-Rs.
I
midazole-4-acetic acid (IAA) is a ␥-aminobutyric acid type A receptor agonist and a low-efficacy, partial agonist at ␥-aminobutyric acid type C receptors (1) , and in the CNS it mediates such effects as analgesia, sedation, hypnosis, aggression, and hypotension (1) (2) (3) (4) . Originally, IAA was thought not to exist in the brain but, using GC͞MS, we showed (5, 6) its presence in perfused rat brain and cerebrospinal fluid. IAA can derive from transamination of histidine or oxidation of histamine (7) (8) (9) . The former is likely to be the main pathway in the CNS, because there, histamine is mainly methylated. In addition, regional CNS levels of IAA (G.D.P., unpublished data) correlated with those of histidine transaminase (also termed kynurenine aminotransferase) (10) but not with those of histamine or its synthetic enzyme, and inhibition of histamine synthesis did not markedly affect IAA levels (11) (12) (13) . Pulse-chase studies showed IAA could be conjugated with phosphoribosyl-pyrophosphate (while hydrolyzing ATP) to produce an IAA-ribotide (14) (15) (16) (17) . The latter can be dephosphorylated by phosphatases and 5Ј nucleotidases (11, 15) to produce an IAA-riboside (7, 8, 11, 15, 18) . Robinson and Green (19) were the first to show traces of IAA-ribotide and IAA-riboside in brains of rats given [ 14 C]histidine (i.p.). However, because brains were not perfused, this finding could have been attributed to circulating conjugates produced by ribosylation in the periphery. Evidence for IAA ribosylation in the CNS came from our studies (11) showing both conjugates in rats given [ 3 H]histamine intracerebroventricularly. These results suggested the existence of endogenous mechanisms for IAA ribosylation in the CNS and were consistent with the observation that levels of IAA conjugates are Ͼ50-fold higher (G.D.P., unpublished data) than those of free IAA (100-200 pmol͞g) in perfused rat brains (5) . The presence of micromolal levels of ribosylated IAA in brain, the requirement for ATP to produce IAA-ribotide (14, 15, 17) , and its rapid turnover (11, 15) led us to hypothesize that IAA-ribotide has a significant physiological role.
To investigate this, we synthesized the two C(1Ј)-N isomers of IAA-ribotide, imidazole-4-acetic acid (I-4-AA-RP) and imidazole-5-acetic acid-ribotide (I-5-AA-RP) ( Fig. 1) , to establish the precise structures of the endogenous conjugates, which had never been determined (7, (14) (15) (16) (17) (18) (19) (20) . We then pursued the hypothesis that endogenous IAA-ribotide may interact with ''imidazoline-Rs'' (I-Rs), formerly the ''imidazole-Rs'' postulated by Karppanen and coworkers (4, 22, 23) . [The concept of I-Rs arose from the fact that some effects of imidazoline-like ␣-adrenergic receptor (␣-R) ligands (e.g., clonidine) are blocked by imidazoles and imidazolines and are incompletely mimicked or blocked by drugs lacking similar structures, such as the catecholamines (4, (24) (25) (26) .] Three I-R subclasses are known. I 1 Rs and I 3 Rs regulate processes, such as sympathetic outflow and blood pressure by the rostroventrolateral medulla (RVLM), and the release of arachidonic acid (AA) from PC12 cells and of insulin from pancreatic islets (25) (26) (27) (28) (29) . I 1 Rs have been characAbbreviations: IAA, imidazole-4-acetic acid; IAA-RP, IAA-ribotide; IAA-R, IAA-riboside; I-5-AA-RP, imidazole-5-acetic acid-ribotide; RVLM, rostroventrolateral medulla; CDS, clonidine-displacing substance; I-R, imidazol(in)e receptor; AA, arachidonic acid; ␣2R, ␣2-receptor; alk-Pase, alkaline phosphatase; MAP, mean arterial pressure; HR, heart rate; SH, spontaneously hypertensive.
b To whom correspondence should be addressed. E-mail: george.prell@mssm.edu. terized pharmacologically and a candidate cDNA has been cloned (30) , whereas I 3 Rs are associated with the exocytotic pathway in pancreatic beta cells, which may include K ATP ϩ channels (26, 28, 29, 31, 32) . I 2 Rs are binding sites on monoamine oxidases and possibly other proteins (33) . The initial suggestion that IAA-ribotide may be an I-R ligand came from our observation that it had physicochemical properties m similar to those of an unidentified endogenous substance(s) reported to act at I 1 Rs and I 3 Rs (25, 26, (34) (35) (36) (37) (38) . This substance(s), extracted from mammalian tissue, was proposed as a putative I-R ligand and called clonidine-displacing substance (CDS), on the basis of its ability to displace the imidazoline drug clonidine (or its congeners) from I-R-specific sites. Some CDSs may contain a group of substances rather than a single entity, but, thus far, only one, agmatine, has been identified in one preparation (25, 26) . However, agmatine binds mainly to I 2 sites (where its role is unknown), has actions unrelated to I-Rs (39) , and lacks significant activity at I 1 Rs and I 3 Rs (25, 26) . Here, we demonstrate that I-4-AA-RP is the endogenous ribotide isomer (Fig. 1) and we show that I-4-AA-RP is an agonist for I 1 Rs and I 3 Rs.
Materials and Methods
Chemical Synthesis. We synthesized I-4-AA-RP-Na 2 and I-4-AA-R HCl (Fig. 1) by modification of the method described for I-5-AA-RP and I-5-AA-R (21) . Before that report, structures of even synthetic IAA conjugates were unknown (40, 41) .
Animal and Tissue Sources. Animal Care and Use Committees of the authors' institutions approved all animal experiments. Human pancreata were harvested from heart-beating cadaver organ donors with next of kin's consent. Sprague-Dawley rats were used in most studies. Spontaneously hypertensive (SH) rats were used in blood pressure and IAA-RP release studies. Animals were obtained commercially.
Identification of IAA-Ribotide by HPLC. Bovine brain CDS (42) , human cerebrospinal fluid, and rat brain extracts (12, 13) were eluted from Dowex-AG-acetate columns (1-3 N acetic acid) and analyzed by HPLC (43) . Authentic IAA-ribotides ( Fig. 1 ) and biological samples, equilibrated with 10 mM H 3 PO 4 (pH 2.85), were eluted with a 2.5-62% KH 2 PO 4 buffer (750 mM, pH 4.4) gradient. Other endogenous imidazoles, nucleotides, and nucleosides (e.g., IAA, IAA-R, AMP, and ATP) have retention times different from IAA-ribotides or negligible absorbance at 220 nm. A 220 of both isomers correlated with quantity (0.02-20 g; r ϭ 0.96, P Ͻ 0.01); their elution times differed by Ϸ3 min.
Alkaline Phosphatase (Alk-Pase) Hydrolysis of CDS. Because [ 3 H]IAA-ribotide produced in vivo was cleaved by alk-Pase (11), we examined whether CDS contains a ribose-P. Samples containing 26.2 units of CDS (42) were incubated (4 h in 250 l) with 20 units of alk-Pase (Sigma) in activation buffer (50 mM Tris⅐HCl͞5 mM MgCl 2 , pH 7.7, 37°C), thermally inactivating (4°C) medium, or alk-Pase inactivation buffer (5 mM EDTA). Samples were then assayed for CDS-binding activity (42) . (One unit ϭ amount of CDS that inhibits 50% of I 1 R-specific [ Affinity-Purified Anti-IAA-RP Abs. Anti-IAA-RP sera were raised in rabbits immunized with I-4-AA-RP linked to keyhole limpet hemocyanin by using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (Sigma). Cross-reactivities were eliminated by successive solid-phase adsorptions of serum with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide-modified BSA, AMP-BSA, ATP-BSA, and rat serum proteins. Purified Abs were obtained by affinity chromatography with I-4-AA-RP bound to agarose.
Quantitative ELISA. Rat brain homogenates were boiled, cooled, and centrifuged. Supernatants, extracted with butanol͞chloroform (5, 6, 12, 13), were mixed with an equal volume of anti-IAA-RP Abs (3% BSA, 20 mM PBS). After incubation (37°C, 1 h), four 100-l samples were incubated (16 h, 4°C) in plates coated with I-4-AA-RP-BSA. Wells were washed, reacted (37°C, 1 h) with peroxidaselabeled goat anti-rabbit Abs (Kirkegaard & Perry Laboratories), washed again, then developed with ABTS or TMB substrates (Kirkegaard & Perry Laboratories). I-4-AA-RP levels were estimated from standard inhibition curves (1 pmol-10 nmol). Controls included samples devoid of I-4-AA-RP, anti-I-4-AA-RP sera, or secondary Ab. To study IAA-RP released from P 2 preparations (0.08-20 pmol), protein-free supernatants (in 10% trichloroacetic acid) and biotinylated goat anti-rabbit Abs and peroxidasestreptavidin were used.
Immunocytochemistry. Anesthetized rats were perfused transcardially with 100 ml of PBS (room temperature), 100 ml of 4% 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide in PBS (room temperature), then 300 ml of 4% paraformaldehyde (4°C). Islets of Langerhans from male Wistar rats and human pancreata were isolated by collagenase digestion. Hand-picked islets were incubated in NaHCO 3 -buffered saline containing 1 mM CaCl 2 , 1 mg͞ml BSA, and test reagents. After incubation, insulin levels in supernatants were analyzed by radioimmunoassay. The I 3 blocker, KU-14R, served to verify I 3 R function. 
Effects of Ribotide on Mean Arterial Pressure (MAP) and Heart Rate (HR).
Bilateral I-4-AA-RP microinjections (60 nl, 100 nmol) into the RVLM of SH rats were performed (48) after the sympathoexcitatory area was confirmed by showing glutamate-induced MAP elevation of Ն30 mmHg (1 mmHg ϭ 133 Pa). MAP and HR values were measured every 5 min. After each experiment, the injection site was marked by infusion of rhodamine microspheres. Changes were assessed relative to baseline values by two-way repeated-measures ANOVA and Dunnett's test. A second group of SH rats (injection controls) received vehicle injections to control for injection effects and for volume artifacts due to multiple injections. Vehicle contained 2 nmol of rilmenidine, a subthreshold dose, far below that known to cause any detectable effect (49) . In a follow-up study, SH rats (n ϭ 6) were given I-4-AA-RP then moxonidine. When used alone, the latter reduced MAP to normotensive levels (50) . Fig. 2 C and F) , whereas a novel peak appeared in samples mixed with I-5-AA-RP (Fig. 2D ). These observations demonstrate that the I-4-AA-RP isomer (Fig. 1 , hereafter denoted as ''IAA-RP'') is present in tissues (Fig. 2) and in cerebrospinal fluid (data not shown). Its endogenous metabolite is therefore I-4-AA-R, hereafter denoted ''IAA-R.'' [IAA-R has also been found in samples from rats and humans by using GC͞MS (unpublished data).]
Specificity of Anti-IAA-RP Abs and Quantitative ELISA. Purified anti-IAA-RP Abs showed negligible cross-reactivity with Ͼ50 compounds (10 nM-0.1 mM), including free and BSA-conjugated imidazoles, such as IAA-R, I-5-AA-RP, I-5-AA-R, and IAA; related endogenous and synthetic pyrimidine-and purineribose-Ps (e.g., ZMP, AMP, ADP, ATP, cAMP, and cGMP); and unconjugated compounds, such as histidine and histamine, and their metabolites. Others included phosphatase and 5Ј nucleotidase inhibitors and compounds relevant to the imidazol(in)e field, e.g., clonidine, cimetidine, efaroxan, KU-14R, agmatine, and idazoxan. Abs did not stain Western blots of rat brain homogenates.
Quantitative ELISA confirmed that rat brain extracts contained IAA-RP (1.1 Ϯ 0.6 g͞g tissue, n ϭ 8).
IAA-RP Is Present in Brainstem Neurons
. RVLM neurons stained intensely in sections reacted with anti-IAA-RP Abs (Fig. 3A) . Neuropil staining due to the presence of IAA-RP in neuronal processes was also intense. Myelinated axon bundles were unstained (Fig. 3) . Adjacent sections treated with primary Abs preabsorbed with IAA-RP (Fig. 3B ), preimmune serum, or with secondary Abs (horse anti-rabbit) alone showed no appreciable immunoreactivity. Neuronal staining was present in other brainstem areas, e.g., the solitary, gracile, vestibular, ventral cochlear, medial parabrachial and inferior olivary nuclei, and Purkinje cell somata and dendrites of the cerebellar cortex.
Alk-Pase Depleted CDS Activity. Treatment with active alk-Pase decreased CDS activity from 26.2 to 6.7 units (Ϫ74%); inactivated enzyme had no effect. Therefore, a substance containing a hydrolyzable P-monoester appeared to mediate most of the CDS activity (42) consistent with conversion of IAA-RP to IAA-R.
IAA-RP Binds to Adrenal Medulla I1R Sites and Is an I1R Agonist in PC12
Cells. The adrenal medulla does not express ␣ 2 -sites and is a model for I 1 R binding (27, 44 Fig. 4 ; P Ͻ 0.05; n ϭ 13); 100 M elicited a larger response (177 Ϯ 89%; P Ͻ 0.05, n ϭ 6; data not shown). In contrast, IAA-R (10 M to 1 mM) showed no significant response. The I 1 antagonist͞I 3 agonist efaroxan abolished responses to IAA-RP (Fig. 4) .
IAA-RP Is an I3R Agonist. Potentiation of glucose-induced insulin release is the best-characterized I 3 R-mediated response (26, 28, 29) . As reported for CDS and other I 3 R agonists (28, 29, 51) , IAA-RP increased insulin secretion from islets (Fig. 5) . It also overcame inhibitory effects of the K ATP ϩ -channel agonist, diazoxide (Fig. 5) . These IAA-RP effects are characteristic of I 3 R agonists, but, significantly, IAA-RP was far more potent than efaroxan (Fig. 5A) , the prototypical I 3 agonist͞I 1 antagonist. IAA-RP stimulation was biphasic in rat ( Fig. 5B) and human islets. In rats, IAA-RP had an EC 50 of 30-50 nM. Human islets appeared to be even more sensitive, displaying an EC 50 of Ϸ3 nM. The I 3 R antagonist KU-14R (28) abolished IAA-RPinduced secretion (Fig. 5C ), confirming I 3 R activity. (Fig. 6) were biphasic, consisting of both highand low-affinity sites. In the absence of I-R and ␣ 2 -masking ligands, the high-affinity component comprised 71 Ϯ 5% (X Ϯ SEM) of total binding (K I , 160 Ϯ 38 nM). The remaining sites showed Ͼ300-fold lower affinity for IAA-RP (K I , 57 Ϯ 33 M). After masking ␣ 2 Rs with epinephrine, IAA-RP high-affinity binding accounted for 86 Ϯ 4% of total binding (K I , 100 Ϯ 19 nM); the K I of low-affinity sites was 60 Ϯ 48 M. Conversely, when I sites were masked with the imidazole cimetidine, IAA-RP high-affinity binding was abolished and only low-affinity sites remained (presumably ␣ 2 -Rs; K I , 210 Ϯ 32 M). Thus, in the RVLM, IAA-RP exhibited high affinity for I-R sites and was Ͼ1,000-fold more selective for I-Rs than for presumed ␣ 2 -sites. In parallel assays, IAA-R had very low affinity (K I , 266 Ϯ 48 M; not shown).
IAA-RP Has

IAA-RP Shows Ca 2؉ -Dependent Release from Neuronal Terminals.
IAA-RP release from P 2 nerve endings was studied. IAA-RP levels in controls showed little variation (Յ11%) within each preparation but varied considerably among preparations (5.7-35.5 fmol͞l). Nevertheless, a significant net effect was observed (P Ͻ 0.05, ANOVA). Mean IAA-RP release in samples containing Ca 2ϩ exceeded by 40.3% (P ϭ 0.03, Wilcoxon's test) the mean (and the median by 49%) of controls grouped together (X Ϯ SEM: 22.7 Ϯ 4.8 fmol͞l) (i.e., nondepolarized preparations or those deprived of Ca 2ϩ by EDTA). These data demonstrate that IAA-RP is stored in fractions that contain synaptic endings and IAA-RP undergoes depolarization-induced release consistent with transsynaptic function.
Microinjection of IAA-RP into the RVLM Produces Hypertension. SH rats were used as a model system (50), because IAA-RP, as an I 1 agonist (Fig. 4) , was expected to lower MAP. Yet, IAA-RP immediately raised MAP an average of Ϸ25 mmHg over baseline ( Fig. 7A ; P Ͻ 0.01, ANOVA; n ϭ 6). A second microinjection 20 min later again raised MAP ( Fig. 7A ; P Ͻ 0.05). In contrast, HR showed no significant changes. IAA-R (100 nmol; n ϭ 3; data not shown) did not alter MAP or HR significantly. Injection alone (injection controls) did not alter HR or MAP (Fig. 7B) , confirming that MAP elevations were due to IAA-RP. In a smaller study using normotensive rats (n ϭ 3), IAA-RP produced a similar hypertensive response. To assess whether IAA-RP's effect could be reversed, the I 1 agonist moxonidine (MOX; 4 nmol) was microinjected into SH rats whose MAP had been elevated (20.4 Ϯ 5.6% above baseline) after six 100-nmol doses of IAA-RP. MOX completely reversed IAA-RP's effect and lowered MAP (37.3 Ϯ 6.3%) toward normotensive levels within 30 min. This finding further suggests that IAA-RP's hypertensive effect was not mediated by I 1 Rs.
Discussion
This report addresses the identification of the structure of the endogenous IAA-RP isomer, the ability of the latter to interact with I-Rs, and the physiological significance of such interactions. HPLC studies (Fig. 2) of tissue extracts revealed the biological isomer to be I-4-AA-RP (Fig. 1) . Its presence in brainstem regions and, in particular, in the RVLM (Fig. 3) is significant, because this region is an important site of action for a class of antihypertensive agents that are thought to exert their effects by means of I 1 Rs (48-50). Several observations indicate that IAA-RP is an I-R agonist. First, IAA-RP bound to prototypical I 1 Rs in adrenal tissue and promoted AA release from PC12 cells (Fig. 4) . Second, IAA-RP induced a robust stimulatory response in pancreatic islets (Fig. 5) , consistent with I 3 R activity. In fact, IAA-RP was unusually potent (EC 50 , 30-50 nM; Fig. 5B ) in comparison with efaroxan, the prototypical I 3 agonist, which typically shows maximal stimulation at Ϸ100 M (28, 31) . Notably, similar responses were elicited by CDS (28, 51), a putative but unidentified endogenous I-R ligand. Because our CDS preparation contained IAA-RP (Fig. 2) , and alk-Pase abolished most of CDS's activity, we surmise that CDS I-R activity might derive from IAA-RP. Historically, CDS was first shown to displace clonidine from ␣ 2 Rs (25, 26, (34) (35) (36) (37) (38) . Thus, if IAA-RP is the active factor in CDS, then it might also be expected to act at ␣ 2 Rs. Although we have not studied this formally, IAA-RP's biphasic response (Fig. 5B ) in islets provides physiological evidence consistent with the possibility that submicromolar levels of IAA-RP stimulate insulin release, but higher levels are inhibitory. Considering that IAA-RP affinity for I-Rs vastly exceeds that for (presumed) ␣ 2 -sites (Fig. 6) , the stimulatory phase can be explained by I-R activation whereas the inhibition may be due to ␣ 2 R activation (29) .
Some of our observations were unexpected because, as an I 1 agonist (Fig. 4) , IAA-RP injection into the RVLM was expected to lower blood pressure, as has been observed with other I 1 agonists (48, 50) . Instead, as observed with CDS in normotensive rats (35) , IAA-RP produced a rapid, transient increase in MAP (Fig. 7A) , despite approaching MAP ceiling effects in SH rats. These observations compelled us to reconsider the actions of I-Rs within the RVLM, where I-R activity has been attributed to I 1 sites because its pharmacological profile was consistent with that of I 1 R models (27, 48) . The most direct explanation for our results is that the RVLM contains two cimetidine-sensitive I-R subtypes, I 1 Rs and an undefined I-R subtype, which regulate blood pressure in a reciprocal manner. This contention is supported by the fact that the IAA-RP binding profile in the RVLM [which exhibits both highand low-affinity sites (Fig. 6) ] differs markedly from that of the single site observed in adrenal tissue, which contains prototypical I 1 R sites. Affinities of high-affinity sites were Ͼ100-fold greater than those of both low-affinity RVLM sites and adrenal I 1 R sites. Furthermore, when ratios of affinities of the IAA-RP and IAA-R pair were considered, the K I (IAA-RP, low-affinity)͞K I (IAA-R) ratio in the RVLM was nearly the same as the K I (IAA-RP)͞K I (IAA-R) ratio in adrenal tissue. Yet, both ratios were orders of magnitude different from the K I (IAA-RP, high-affinity)͞K I (IAA-R) ratio in the RVLM. Taken together, our data suggest that in the RVLM the low-affinity site is I 1 R-like and that IAA-RP's hypertensive effect (Fig. 7) derives from a non-I 1 R, high-affinity site. Although the nature of this putative receptor is unknown, we note that the K I of the high-affinity site (100 nM; Fig. 6 ) appears to be congruent with its EC 50 at I 3 Rs (30-50 nM; Fig. 5B) , and that the I 3 agonist efaroxan also induces hypertension when injected into the RVLM (27, 44) . Because evidence exists that, in islets, I 3 agonists interact with K ATP ϩ channels (28, 29) , that the latter are abundant in the RVLM (52) , and that imidazol(in)e-induced closure of K ATP ϩ channels promotes cellular excitability (51), we hypothesize that a site(s) related to these channels may mediate the effects of IAA-RP. Thus, the proposition that IAA-RP might act by means of midbrain I 3 -like-Rs merits further consideration.
Our data suggest that IAA-RP may participate in transsynaptic signaling in brain, because it exists in brainstem neurons (Fig. 3) , exhibits depolarization-induced Ca 2ϩ -dependent release from P 2 synaptosomal elements, has relatively high affinity for membranebound I-R sites (Fig. 6) , and produces physiological effects on exogenous application (Fig. 7A) . IAA-RP is rapidly metabolized by phosphatases and ecto-5Ј-nucleotidases (11, 15) (G.D.P., unpublished data), both membrane-bound, to produce IAA-R, which has far less activity than IAA-RP. This would be compatible with a mechanism for rapid removal of IAA-RP so as to regulate its synaptic levels. Collectively, these observations meet the major requirements (53) to suggest that IAA-RP is a neurotransmitter. Although more definitive assertions await further studies, to date we have found nothing inconsistent with this hypothesis. Thus, one can speculate how IAA-RP might tonically overstimulate brainstem I-Rs to produce hypertension. The potent stimulation of insulin release by IAA-RP, its ability to induce AA release, and IAA-R's presence in plasma and urine (7) (8) (9) 18 ) also suggest that IAA-RP might exert hormone-like activity in the periphery. Indeed, IAA-RP's actions in the RVLM and in the pancreas reported here suggest it could be a link connecting the disorders of hypertension and diabetes (24, 28, 29, 48) .
We acknowledge that different preparations of CDS (25, (34) (35) (36) (37) (38) 42 ) may contain variable amounts of IAA-RP and͞or other potentially active substances. [One possibility is harmane (54) .] Nevertheless, our data provide evidence that IAA-RP has a hitherto unrecognized physiological and͞or pathophysiological function in the CNS and periphery.
